Century Therapeutics (NASDAQ: IPSC) is a clinical-stage biopharmaceutical company developing allogeneic cell therapies derived from induced pluripotent stem cells (iPSCs). The company generates no product revenue as of its 10-K filed March 12, 2026, and funds operations through equity offerings, debt financings, and license or development agreements. Its lead product candidate, CNTY-101, is an iPSC-derived CAR-expressing cell therapy progressing through preclinical and clinical development. The company holds three issued U.S. patents and 24 pending U.S. patent applications covering engineered iPSC cells, cell differentiation technology, and cellular immunotherapy compositions, including its proprietary Allo-Evasion technology. Research and development expenses represent the primary use of capital, directed at expanding iPSC cell therapy platforms, conducting clinical trials, and building clinical-scale cGMP manufacturing capabilities. Century expects continued operating losses and additional capital raises for the foreseeable future.

Revenue model

No product revenue as of the 10-K filed March 12, 2026. The company finances operations through equity offerings, debt financings, and potentially through license and development agreements or strategic partnerships with third parties.

Products and services

CNTY-101, an iPSC-derived CAR-expressing cell therapy, is the lead clinical product candidate. The pipeline also includes iPSC-derived alpha-beta and gamma-delta T-cell platforms and beta-islet cell programs. The company's proprietary technologies include Allo-Evasion, CRISPR-mediated precision gene editing for transgene incorporation and gene disruption, and a safety switch construct covered by issued U.S. Patent No. 11,661,459 and U.S. Patent No. 12,269,888.

Customers and end markets

No commercial customers as of the 10-K filed March 12, 2026. End markets are oncology and potentially other diseases treatable by cellular immunotherapy, pending regulatory approval of product candidates.

Value-chain role

Preclinical and clinical-stage drug developer. Relies on contract manufacturing organizations (CMOs) and suppliers, including FUJIFILM Cellular Dynamics Inc. (FCDI), for biological materials and manufacturing. Building internal clinical-scale cGMP manufacturing facilities.

Geographic exposure

Operations based in the United States. Patent portfolio consists of U.S. patents and PCT applications. No geographic revenue mix disclosed given pre-revenue stage.

Source: SEC 10-K, filed 2026-03-12

Industry: Biological Products, (No Diagnostic Substances) Peers: Adicet Bio Inc Agenus Inc Cullinan Therapeutics Inc Immunovant Inc Inhibrx, Inc. Janux Therapeutics Inc Kezar Life Sciences Inc Vanda Pharmaceuticals Inc Vera Therapeutics, Inc